Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 24 Oct 2018 Primary endpoint (Proportion of subject who achieve clinical remission (CDAI 150) at week 4) has been met, according to results presented at the 26th United European Gastroenterology Week.
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week.
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.